Clinical proteomics and breast cancer

Zeidan, Bashar; Townsend, Paul A.; Garbis, Spiros D.; Copson, Ellen; Cutress, Ramsey I.

doi:10.1016/j.surge.2014.12.003

Cited by 36 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 41 Furthermore, numerous proteomic studies of breast cancer have been accomplished aiming to aid the development of personalized therapies, increase understanding of post treatment relapse, and help improve prediction of patient prognosis. 56 …”

Section: Diagnosis Of Breast Cancermentioning

confidence: 99%

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

Nounou

ElAmrawy

Ahmed

et al. 2015

Breast Cancer�(Auckl)

240

208

View full text Add to dashboard Cite

Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer.HIGHLIGHTSBreast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments.Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease.Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management.Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application.Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.

show abstract

Section: Diagnosis Of Breast Cancermentioning

confidence: 99%

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

Nounou

ElAmrawy

Ahmed

et al. 2015

Breast Cancer�(Auckl)

240

208

View full text Add to dashboard Cite

show abstract

“…Therefore, new methods for the early detection of breast cancer are required to support high risk younger women. The search for diagnostic biomarkers of breast cancer has been extensive and proteomics strategies increasingly employed as part of the discovery process [10]. Plasma is by far the most common biofluid used, but putative markers are massively diluted relative to the site of origin of the cancer, thereby reducing sensitivity [11].…”

Section: Clinical Relevancementioning

confidence: 99%

“…As plasma is by far the most commonly used and most completely characterized liquid biopsy for diagnosing disease, including breast cancer [10], we wanted to establish if the NAF proteome is likely to provide unique insights. The Plasma Proteome Database comprises the collated quantitative data for 10 546 proteins that have been detected in plasma and serum using immunoassays or mass spectrometric techniques (http://www.plasmaproteomedatabase.org/) [25].…”

Section: Naf Proteomic Analysismentioning

confidence: 99%

Nipple aspirate fluid—A liquid biopsy for diagnosing breast health

Shaheed

Tait

Kyriacou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

PurposeNipple secretions are protein‐rich and a potential source of breast cancer biomarkers for breast cancer screening. Previous studies of specific proteins have shown limited correlation with clinicopathological features. Our aim, in this pilot study, was to investigate the intra‐ and interpatient protein composition of nipple secretions and the implications for their use as liquid biopsies.Experimental designMatched pairs of nipple discharge/nipple aspirate fluid (NAF, n = 15) were characterized for physicochemical properties and SDS‐PAGE. Four pairs were selected for semiquantitative proteomic profiling and trypsin‐digested peptides analyzed using 2D‐LC Orbitrap Fusion MS. The resulting data were subject to bioinformatics analysis and statistical evaluation for functional significance.ResultsA total of 1990 unique proteins were identified many of which are established cancer‐associated markers. Matched pairs shared the greatest similarity (average Pearson correlation coefficient of 0.94), but significant variations between individuals were observed.Conclusions and clinical relevanceThis was the most complete proteomic study of nipple discharge/nipple aspirate fluid to date providing a valuable source for biomarker discovery. The high level of milk proteins in healthy volunteer samples compared to the cancer patients was associated with galactorrhoea. Using matched pairs increased confidence in patient‐specific protein levels but changes relating to cancer stage require investigation of a larger cohort.

show abstract

“…The development of high throughput technologies has made it possible to approach the disease in a global manner and assess the contribution of the DNA, the RNA, and the proteins to the tumorigenic phenotype. While the genomic and transcriptomic levels have been extensively studied, the proteomic level has been mainly studied using cell lines or with low analytical depth due to technological challenges Lam et al, 2014;Lawrence et al, 2015;Sørlie, 2007;Zeidan et al, 2015). Seminal gene expression studies defined molecular signatures that allowed the classification of breast tumors into four accepted ''intrinsic'' subtypes: luminal A and B, Her2-overexpressing, and basal-like tumors (Perou et al, 2000;Sørlie et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

System-wide Clinical Proteomics of Breast Cancer Reveals Global Remodeling of Tissue Homeostasis

et al. 2016

View full text Add to dashboard Cite

The genomic and transcriptomic landscapes of breast cancer have been extensively studied, but the proteomes of breast tumors are far less characterized. Here, we use high-resolution, high-accuracy mass spectrometry to perform a deep analysis of luminal-type breast cancer progression using clinical breast samples from primary tumors, matched lymph node metastases, and healthy breast epithelia. We used a super-SILAC mix to quantify over 10,000 proteins with high accuracy, enabling us to identify key proteins and pathways associated with tumorigenesis and metastatic spread. We found high expression levels of proteins associated with protein synthesis and degradation in cancer tissues, accompanied by metabolic alterations that may facilitate energy production in cancer cells within their natural environment. In addition, we found proteomic differences between breast cancer stages and minor differences between primary tumors and their matched lymph node metastases. These results highlight the potential of proteomic technology in the elucidation of clinically relevant cancer signatures.

show abstract

Clinical proteomics and breast cancer

Cited by 36 publications

References 29 publications

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

Nipple aspirate fluid—A liquid biopsy for diagnosing breast health

System-wide Clinical Proteomics of Breast Cancer Reveals Global Remodeling of Tissue Homeostasis

Contact Info

Product

Resources

About